| SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis X Shangguan, J He, Z Ma, W Zhang, Y Ji, K Shen, Z Yue, W Li, Z Xin, ... Nature communications 12 (1), 1812, 2021 | 84 | 2021 |
| The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer K Shen, B Liu, X Zhou, Y Ji, L Chen, Q Wang, W Xue Frontiers in oncology 11, 683793, 2021 | 39 | 2021 |
| Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy Z Ma, W Zhang, B Dong, Z Xin, Y Ji, R Su, K Shen, J Pan, Q Wang, W Xue Theranostics 12 (11), 4965, 2022 | 35 | 2022 |
| HOXD13 suppresses prostate cancer metastasis and BMP4‐induced epithelial‐mesenchymal transition by inhibiting SMAD1 F Xu, X Shangguan, J Pan, Z Yue, K Shen, Y Ji, W Zhang, Y Zhu, J Sha, ... International journal of cancer 148 (12), 3060-3070, 2021 | 34 | 2021 |
| Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition L Chen, H Liu, Y Ji, Z Ma, K Shen, X Shangguan, H Qian, Y Zhao, ... Experimental cell research 415 (2), 113138, 2022 | 12 | 2022 |
| ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers N Jing, K Zhang, X Chen, K Liu, J Wang, L Xiao, W Zhang, P Ma, P Xu, ... Journal of Clinical Investigation 133 (24), e168670, 2023 | 8 | 2023 |
| Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation R Su, L Chen, Z Jiang, M Yu, W Zhang, Z Ma, Y Ji, K Shen, Z Xin, J Qi, ... Frontiers in Oncology 12, 955166, 2022 | 7 | 2022 |
| Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway Y Ji, B Liu, L Chen, A Li, K Shen, R Su, W Zhang, Y Zhu, Q Wang, W Xue Cellular Oncology 46 (5), 1445-1456, 2023 | 3 | 2023 |
| The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer Y Ji, W Zhang, K Shen, R Su, X Liu, Z Ma, B Liu, C Hu, Y Xue, Z Xin, ... Nature Communications 14 (1), 7794, 2023 | 1 | 2023 |
| 18F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis K Shen, M Yu, Y Ji, X Zhou, B Liu, W Zhang, R Su, J Qi, Q Wang, W Xue The Prostate 83 (12), 1167-1175, 2023 | 1 | 2023 |
| High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer L Chen, Y Ji, A Li, B Liu, K Shen, R Su, Z Ma, W Zhang, Q Wang, Y Zhu, ... Frontiers in Oncology 13, 1085569, 2023 | 1 | 2023 |
